6 New Drugs Enter Phase III Clinical Trials in April 2026, Targeting Rare Diseases Including Systemic Sclerosis and Multiple Myeloma
May 20, 2026 20:59
CST Updated
May 21, 01:30
Suven Life Sciences
Contract Research and Manufacturing Service Provider